Artis BioSolutions has established a new synthetic DNA manufacturing hub in Boston, incorporating its Syngoi Technologies platform at the U.S. facility. The expansion aims to provide critical synthetic DNA capabilities for customers working across early development stages through clinical manufacturing phases.
The Boston hub represents a strategic move to enhance manufacturing capabilities for the growing synthetic biology sector. By localizing Syngoi Technologies in the United States, Artis is positioning itself to better serve domestic clients requiring synthetic DNA components for therapeutic development and research applications.